Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) to identify placebo-controlled or active-controlled RCTs using different GLP-1 RAs. We included eleven placebo-controlled or active-controlled phase-2 RCTs (involving a total of 936 middle-aged individuals) that used liraglutide (n = 6 RCTs), exenatide (n = 3 RCTs), dulaglutide (n = 1 RCT) or semaglutide (n = 1 RCT) to specifically treat NAFLD or NASH, detected by liver biopsy (n = 2 RCTs) or imaging techniques (n = 9 RCTs). Compared to placebo or reference therapy, treatment with GLP-1 RAs for a median of 26 weeks was associated with significant reductions in the absolute percentage of liver fat content on magnetic resonance-based techniques (pooled weighted mean difference: −3.92%, 95% confidence intervals (CI) −6.27% to −1.56%) and serum liver enzyme levels, as well as with greater histological resolution of NASH without worsening of liver fibrosis (pooled random-effects odds ratio 4.06, 95% CI 2.52–6.55; for liraglutide and semaglutide only). In conclusion, treatment with GLP-1 RAs (mostly liraglutide and semaglutide) is a promising treatment option for NAFLD or NASH that warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent meta‐analysis consisting of 11 RCTs that investigated GLP‐1 agonists in NAFLD patients concluded that their overall clinical effect lies mainly in NASH resolution rather than fibrosis improvement [42].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The average HbA1c reduction with GLP-1RA in MASLD studies was estimated to be 0.5 % in individuals with and without type 2 diabetes [104] but may be substantially higher depending on the investigated compound and collective [105].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Specifically, the interpretation of the I 2 -statistics is as follows: I 2 -values of roughly 25% show low heterogeneity, I 2 -values of roughly 50% show medium heterogeneity, whereas I 2 -values of roughly 75% show high heterogeneity [65].”
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“We performed a systematic review and meta-analysis of RCTs in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (http://www.prisma-statement.org) [61].”
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 2×
“In addition, for continuous variables, if not available, SDs of the mean differences were estimated using the following formula: SD = [(SD pre-treatment) 2 + (SD post-treatment) 2 − (2R × SD pre-treatment × SD post-treatment)] 12 [64].”
InfluentialLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“Conversely, there is now a large body of evidence showing that treatment with liraglutide or other long-acting GLP-1 RAs exerts beneficial effects on cardiovascular, mortality, and kidney outcomes in people with T2DM [45–49].”
Meta-analysis: Principles and procedures
Egger, M., Smith, G. D., & Phillips, A. N. (1997) · BMJ · doi:10.1136/bmj.315.7121.1533 · Cited by 2,415
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 2×
“Third, in the RCT with semaglutide all participants were randomly assigned to receive once-daily semaglutide at a dose of 0.1 mg, 0.2 mg, 0.4 mg/day or placebo [34].”
InfluentialHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747 · cited 2×
“Strong evidence indicates that T2DM is one of the most important risk factors for faster progression of NAFLD to NASH, cirrhosis and HCC [8–10].”
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“In a systematic review and meta-analysis of seven large cardiovascular outcome trials (involving a total of ~56,000 participants), Kristensen et al. [50] showed that GLP-1 RAs significantly reduced major adverse cardio-vascular events by 12%, all-cause mortality by 12%, hospital admission for heart…”
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 3×
“GLP-1 RAs improve glycemic control while also reducing body weight and insulin resistance [22].”
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,424
Self-citationTaylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D., Win, S., Than, T. A., Abdelmalek, M. F., & Suzuki, A. (2019) · Hepatology · doi:10.1002/hep.30626 · Cited by 1,050
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972 · cited 1×
“In fact, GLP-1 RAs are efficacious for treatment of T2DM and are also able to promote significant weight loss (on average 4–5 kg) [51].”
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) is a metabolic liver disease that encompasses a spectrum of progressive pathological conditions, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC) [1–4].”
Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans
Cheng, S., Rhee, E. P., Larson, M. G., Lewis, G. D., McCabe, E. L., Shen, D., Palma, M. J., Roberts, L. D., Dejam, A., Souza, A. L., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.067827 · Cited by 587 · cited 1×
“The link between insulin resistance and risk of T2DM involves multiple metabolic intermediates that include branched chain and aromatic amino acids, sugars and glycolysis intermediates, as well as ceramides and short-, medium-and long-chain acylcarnitines [15–17].”
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 1×
“Experimental evidence based on both human hepatocytes and animal models also suggests that GLP-1 RAs are able to improve hepatic steatosis by reducing de novo lipogenesis, enhancing oxidation of fatty acids and improving multiple elements of the insulin signaling pathways [52–56].”
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C. D., & Targher, G. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154170 · Cited by 553 · cited 2×
“…once-daily subcutaneous treatment with liraglutide or semaglutide on resolution of NASH and/or improvement in liver fibrosis stage, which are the two histological features of NAFLD most strongly associated with risk of adverse liver-related and extra-hepatic outcomes in people with NAFLD [10,42–44].”
Self-citationGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · cited 1×
“Moreover, preclinical NASH studies also suggested that GLP-1 RAs may reduce hepatic inflammation through mechanisms that are at least in part independent of body weight reduction [57].”
Mantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C. D., & Targher, G. (2021) · Gut · doi:10.1136/gutjnl-2020-322572 · Cited by 481 · cited 1×
“…once-daily subcutaneous treatment with liraglutide or semaglutide on resolution of NASH and/or improvement in liver fibrosis stage, which are the two histological features of NAFLD most strongly associated with risk of adverse liver-related and extra-hepatic outcomes in people with NAFLD [10,42–44].”
Self-citationEpidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
Lonardo, A., Bellentani, S., Argo, C. K., Ballestri, S., Byrne, C. D., Caldwell, S. H., Cortez-Pinto, H., Grieco, A., Machado, M. V., Miele, L., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.08.004 · Cited by 444
Self-citationSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397 · cited 1×
“Over the last decade, it has become increasingly clear that NAFLD, especially NASH with advanced stages of fibrosis, also increases the risk of chronic vascular complications of diabetes [11].”
Self-citationAISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.147 · Cited by 306 · cited 2×
“Nonalcoholic fatty liver disease (NAFLD) is a metabolic liver disease that encompasses a spectrum of progressive pathological conditions, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC) [1–4].”
Self-citationTrevaskis, J. L., Griffin, P. S., Wittmer, C., Neuschwander-Tetri, B. A., Brunt, E. M., Dolman, C. S., Erickson, M. R., Napora, J., Parkes, D. G., & Roth, J. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2011 · Cited by 277 · cited 1×
“Experimental evidence based on both human hepatocytes and animal models also suggests that GLP-1 RAs are able to improve hepatic steatosis by reducing de novo lipogenesis, enhancing oxidation of fatty acids and improving multiple elements of the insulin signaling pathways [52–56].”
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250 · cited 1×
“After examining the full text of these 15 articles, we excluded four studies [35–38] because of unsatisfactory inclusion criteria or unsatisfactory outcome measures, as specified in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.”
Kuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05265-7 · Cited by 249 · cited 1×
“This is the largest and most updated assessment to date on the efficacy of GLP-1 RAs to specifically treat NAFLD or NASH that has also included the most recently published RCTs using two long-acting GLP-1 RAs, such as dulaglutide and semaglutide [33,34].”
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Dufour, J.-F., Caussy, C., & Loomba, R. (2020) · Gut · doi:10.1136/gutjnl-2019-319104 · Cited by 193 · cited 1×
“Several drug molecules with different mechanisms of action are under development to treat this common and burden-some liver disease, although their efficacy has been limited [18].”
Newsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15316 · Cited by 186 · cited 1×
“After examining the full text of these 15 articles, we excluded four studies [35–38] because of unsatisfactory inclusion criteria or unsatisfactory outcome measures, as specified in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.”
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
Serum Levels of Acylcarnitines Are Altered in Prediabetic Conditions
Mai, M., Tönjes, A., Kovacs, P., Stumvoll, M., Fiedler, G. M., & Leichtle, A. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082459 · Cited by 178
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178
Idilman, I. S., Keskin, O., Celik, A., Savas, B., Halil Elhan, A., Idilman, R., & Karcaaltincaba, M. (2016) · Acta Radiologica · doi:10.1177/0284185115580488 · Cited by 168 · cited 1×
“In addition, most of the included RCTs have used magnetic resonance-based techniques, which have been shown to accurately quantify changes in liver fat content [58].”
Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?
Gruben, N., Shiri‐Sverdlov, R., Koonen, D. P. Y., & Hofker, M. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.08.004 · Cited by 167 · cited 2×
“Insulin resistance is one of the key components of the metabolic syndrome and an established risk factor for the development of T2DM [14].”
Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12555 · Cited by 164
Lonardo, A., Mantovani, A., Lugari, S., & Targher, G. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.03.001 · Cited by 150 · cited 1×
“It has been estimated that NAFLD affects up to ~30% of the general population and up to ~70–80% of people with either T2DM or obesity [5–7].”
Self-citationMantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138 · cited 4×
“To our knowledge, compared to recently published systematic review articles on this topic [20,36,40,41], this is the largest and most updated systematic review and metaanalysis of RCTs that used different GLP-1 RAs (also including two newer long-acting injectable GLP-1 RAs, such as dulaglutide and semaglutide), for th…”
InfluentialSelf-citationKhoo, J., Hsiang, J. C., Taneja, R., Koo, S., Soon, G., Kam, C. J., Law, N., & Ang, T. (2019) · Liver International · doi:10.1111/liv.14065 · Cited by 136
Lonardo, A., & Suzuki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051278 · Cited by 129 · cited 1×
“…differences in the prevalence, risk factors and clinical outcomes of NAFLD are a distinctive and recently identified feature of NAFLD and NASH [59,60], future adequately powered RCTs should be specifically designed to explore sex differences in the response rate of NAFLD and NASH to treatment…”
Self-citationBizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W. (2020) · Diabetologia · doi:10.1007/s00125-019-05021-6 · Cited by 123 · cited 1×
“We initially identified 15 potentially relevant RCTs from PubMed, Scopus and ClinicalTrials.Gov databases until to 15 December 2020 [25–39].”
Liu, L., Yan, H., Xia, M., Zhao, L., Lv, M., Zhao, N., Rao, S., Yao, X., Wu, W., Pan, B., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3292 · Cited by 118
Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults
Byrne, C. D., Patel, J., Scorletti, E., & Targher, G. (2018) · BMJ · doi:10.1136/bmj.k2734 · Cited by 108
Self-citationCusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13697 · Cited by 89
Tang, W., Xu, Q., Hong, T., Tong, G., Feng, W., Shen, S., Bi, Y., & Zhu, D. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2713 · Cited by 63 · cited 1×
“To our knowledge, compared to recently published systematic review articles on this topic [20,36,40,41], this is the largest and most updated systematic review and metaanalysis of RCTs that used different GLP-1 RAs (also including two newer long-acting injectable GLP-1 RAs, such as dulaglutide and semaglutide), for th…”
Li, J., Albajrami, O., Zhuo, M., Hawley, C. E., & Paik, J. M. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02690320 · Cited by 61 · cited 1×
“Large RCTs on GLP-1 RAs have also consistently demonstrated that these drugs exert beneficial effects on the risk of adverse cardiovascular outcomes, all-cause mortality and worsening of nephropathy in patients with T2DM [22–24].”
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 61 · cited 2×
“…that long-term use of pioglitazone in adults with biopsy-proven NASH has beneficial effects on the histological resolution of NASH, this drug may have some side-effects, such as moderate weight gain, peripheral oedema and risk of distal bone fractures (especially in postmenopausal women) [12,20,21].”
Panunzi, S., Maltese, S., Verrastro, O., Labbate, L., De Gaetano, A., Pompili, M., Capristo, E., Bornstein, S. R., & Mingrone, G. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14304 · Cited by 61 · cited 1×
“…with biopsy-proven NASH showed that pioglitazone and bariatric surgery are the two most effective treatment options for NASH, thereby supporting the notion that weight loss and improvement in hepatic insulin resistance are promising approaches for the treatment of this metabolic liver disease [19].”
Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005325 · Cited by 59 · cited 1×
“To our knowledge, compared to recently published systematic review articles on this topic [20,36,40,41], this is the largest and most updated systematic review and meta-analysis of RCTs that used different GLP-1 RAs (also including two newer long-acting injectable GLP-1 RAs, such as dulaglutide and…”
Sachinidis, A., Nikolic, D., Stoian, A. P., Papanas, N., Tarar, O., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
Dhir, G., & Cusi, K. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000554 · Cited by 53
Cusi, K. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 51 · cited 1×
“…that long-term use of pioglitazone in adults with biopsy-proven NASH has beneficial effects on the histological resolution of NASH, this drug may have some side-effects, such as moderate weight gain, peripheral oedema and risk of distal bone fractures (especially in postmenopausal women) [12,20,21].”
A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K. J., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A., & Harrison, S. A. (2021) · Yearbook of pediatric endocrinology · doi:10.1530/ey.18.15.7 · Cited by 33
Muilwijk, M., Goorden, S. M. I., Celis-Morales, C. A., Hof, M. H. P., der Vlugt, K. G., Stet, F. S., Gill, J. M. R., Vaz, F. M., & van Valkengoed, I. G. M. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001003 · Cited by 30 · cited 1×
“The link between insulin resistance and risk of T2DM involves multiple metabolic intermediates that include branched chain and aromatic amino acids, sugars and glycolysis intermediates, as well as ceramides and short-, medium-and long-chain acylcarnitines [15–17].”
Kalogirou, M., Patoulias, D., Haidich, A., Akriviadis, E. A., & Sinakos, E. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.10.012 · Cited by 17
Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD
Targher, G. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15906 · Cited by 4 · cited 1×
“Therefore, early recognition of NAFLD and monitoring of NASH with advanced fibrosis in people with T2DM are crucial [12,13].”
Self-citation
Cited by
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
Metabolic Dysfunction–Associated Steatotic Liver Disease
Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412865 · Cited by 325
Self-citationCurrent treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Self-citation
Metadata
- Authors
- Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G.
- Affiliations
- University of Verona (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Corresponding author
- Targher, Giovanni
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2021-01-27
- Volume
- 11
- Issue
- 2
- Pages
- 73
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC7911747
- OpenAlex
- W3126030429
- Cited by
- 299
- References
- 68
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 54 · 2023: 61 · 2022: 61 · 2021: 35
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- GLP-1 receptor agonists, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liraglutide, semaglutide, exenatide, dulaglutide, liver fat, liver enzymes, liver fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.